Drug Profile
Olendalizumab - Alexion AstraZeneca Rare Disease
Alternative Names: ALXN-1007Latest Information Update: 27 Sep 2021
Price :
$50
*
At a glance
- Originator Alexion Pharmaceuticals
- Developer Alexion AstraZeneca Rare Disease
- Class Anti-inflammatories; Antibodies
- Mechanism of Action Complement C5a inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Antiphospholipid syndrome; Graft-versus-host disease; Inflammation
Most Recent Events
- 27 Sep 2021 Discontinued - Phase-I for Inflammation (In volunteers) in USA (IV) (Alexion pipeline and straZeneca pipeline, September 2021)
- 27 Sep 2021 Discontinued - Phase-II for Antiphospholipid syndrome in France, Brazil, USA, Japan, United Kingdom, Spain, Italy (IV) (Alexion pipeline and straZeneca pipeline, September 2021)
- 27 Sep 2021 Discontinued - Phase-II for Graft-versus-host disease (Newly diagnosed) in USA, France (IV) (Alexion pipeline and straZeneca pipeline, September 2021)